Epoetin alfa--focus on optimal hematocrit. Case study of the anemic patient

Epoetin alfa therapy has dramatically improved therapeutic responses and outcomes for anemic patients with end-stage renal disease. This article examines clinical evidence supporting the correlation between patient outcomes and a higher hematocrit and addresses some of the barriers that may hinder optimal patient outcomes.